Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAMSES OLE: Palforzia extension in peanut allergy
NCT03337542Phase 3Completed
- Start
- Oct 2017
- Primary completion
- Sep 2019
- Modality
- Recombinant Proteins and Enzymes, Allergy Immunotherapy
- Countries
- 2
01
Overview
Phase 3, open-label, single-arm trial of peanut protein in peanut allergy. Primary endpoint: Number of Participants With Treatment-Emergent Adverse Events at 6 months. Started Oct 2017; status: completed.
02
Drugs
peanut protein
03
Conditions
peanut allergy
Beyond the preview
Go deeper on NCT03337542.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03337542.